Barclays Cuts Repligen (NASDAQ:RGEN) Price Target to $175.00

Repligen (NASDAQ:RGEN) had its target price decreased by Barclays from $200.00 to $175.00 in a research note issued to investors on Wednesday morning,Benzinga reports. Barclays currently has an overweight rating on the biotechnology company’s stock.

Several other equities research analysts have also weighed in on the company. Wells Fargo & Company dropped their price target on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research report on Wednesday. Canaccord Genuity Group increased their price objective on Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a report on Wednesday, October 29th. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the company a “hold” rating in a report on Tuesday, October 28th. Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 17th. Finally, Wall Street Zen upgraded shares of Repligen from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $174.58.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $128.73 on Wednesday. Repligen has a 1 year low of $102.96 and a 1 year high of $175.77. The stock has a market capitalization of $7.25 billion, a P/E ratio of 151.45, a P/E/G ratio of 2.54 and a beta of 1.13. The company’s 50-day moving average is $154.18 and its 200 day moving average is $146.80. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.14.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business had revenue of $197.91 million during the quarter, compared to analyst estimates of $192.23 million. During the same period last year, the business posted $0.44 earnings per share. Repligen’s quarterly revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, sell-side analysts expect that Repligen will post 1.72 earnings per share for the current year.

Insider Activity at Repligen

In other news, Director Karen A. Dawes sold 275 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the sale, the director directly owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. This represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

A number of hedge funds have recently bought and sold shares of RGEN. Price T Rowe Associates Inc. MD grew its position in Repligen by 31.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after purchasing an additional 1,091,683 shares during the last quarter. United Capital Financial Advisors LLC purchased a new position in Repligen in the third quarter worth about $368,387,000. Opti Capital Management LP bought a new position in shares of Repligen in the fourth quarter worth approximately $2,399,209,000. Holocene Advisors LP grew its holdings in shares of Repligen by 47.0% during the third quarter. Holocene Advisors LP now owns 1,377,104 shares of the biotechnology company’s stock valued at $184,077,000 after buying an additional 440,290 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Repligen by 43.9% during the fourth quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company’s stock valued at $205,880,000 after buying an additional 383,399 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.